title: Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
abstract: Renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.
authors.affiliation: From the CETIR-ERESA Unidad PET/TC, Barcelona, Spain.
authors.forename: J R
authors.initials: JR
authors.lastname: García Garzon
authors.forename: Pere
authors.initials: P
authors.lastname: Bassa
authors.forename: Elena
authors.initials: E
authors.lastname: Llinares
authors.forename: Marina
authors.initials: M
authors.lastname: Soler
authors.forename: Merce
authors.initials: M
authors.lastname: Moragas
authors.forename: Eduard
authors.initials: E
authors.lastname: Riera
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D020533:Angiogenesis Inhibitors; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18